Translational PBPK modeling and model-informed drug development of IDH305, a complex CYP3A4 modulator
{{output}}
IDH305 was developed as an orally available, mutant-selective, allosteric inhibitor of isocitrate dehydrogenase (IDH)1 for cancer treatment. It is a substrate, time-dependent inhibitor, and inducer of cytochrome P450 (CYP)3A4. As part of model-informed drug de... ...
